Literature DB >> 15317456

Structural basis for the binding of didemnins to human elongation factor eEF1A and rationale for the potent antitumor activity of these marine natural products.

Esther Marco1, Sonsoles Martín-Santamaría, Carmen Cuevas, Federico Gago.   

Abstract

Didemnins and tamandarins are closely related marine natural products with potent inhibitory effects on protein synthesis and cell viability. On the basis of available biochemical and structural evidence and results from molecular dynamics simulations, a model is proposed that accounts for the strong and selective binding of these compounds to human elongation factor eEF1A in the presence of GTP. We suggest that the p-methoxyphenyl ring of these cyclic depsipeptides is inserted into the same pocket in eEF1A that normally lodges either the 3' terminal adenine of aminoacylated tRNA, as inferred from two prokaryotic EF-Tu.GTP.tRNA complexes, or the aromatic side chain of Phe/Tyr-163 from the nucleotide exchange factor eEF1Balpha, as observed in several X-ray crystal structures of a yeast eEF1A:eEF1Balpha complex. This pocket, which has a strong hydrophobic character, is formed by two protruding loops on the surface of eEF1A domain 2. Further stabilization of the bound depsipeptide is brought about by additional crucial interactions involving eEF1A domain 1 in such a way that the molecule fits snugly at the interface between these two domains. In the GDP-bound form of eEF1A, this binding site exists only as two separate halves, which accounts for the much greater affinity of didemnins for the GTP-bound form of this elongation factor. This binding mode is entirely different from those seen in the complexes of the homologous prokaryotic EF-Tu with kirromycin-type antibiotics or the cyclic thiazolyl peptide antibiotic GE2270A. Interestingly, the set of interactions used by didemnins to bind to eEF1A is also distinct from that used by eEF1Balpha or eEF1Bbeta, thus establishing a competition for binding to a common site that goes beyond simple molecular mimicry. The model presented here is consistent with both available biochemical evidence and known structure-activity relationships for these two classes of natural compounds and synthetic analogues and provides fertile ground for future research.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15317456     DOI: 10.1021/jm0306428

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  16 in total

Review 1.  Drug development from marine natural products.

Authors:  Tadeusz F Molinski; Doralyn S Dalisay; Sarah L Lievens; Jonel P Saludes
Journal:  Nat Rev Drug Discov       Date:  2008-12-19       Impact factor: 84.694

2.  Inhibition of translation by cytotrienin A--a member of the ansamycin family.

Authors:  Lisa Lindqvist; Francis Robert; William Merrick; Hideaki Kakeya; Christopher Fraser; Hiroyuki Osada; Jerry Pelletier
Journal:  RNA       Date:  2010-10-13       Impact factor: 4.942

3.  Structural rationale for the cross-resistance of tumor cells bearing the A399V variant of elongation factor eEF1A1 to the structurally unrelated didemnin B, ternatin, nannocystin A and ansatrienin B.

Authors:  Pedro A Sánchez-Murcia; Álvaro Cortés-Cabrera; Federico Gago
Journal:  J Comput Aided Mol Des       Date:  2017-09-12       Impact factor: 3.686

4.  Translation elongation factor 1A facilitates the assembly of the tombusvirus replicase and stimulates minus-strand synthesis.

Authors:  Zhenghe Li; Judit Pogany; Steven Tupman; Anthony M Esposito; Terri Goss Kinzy; Peter D Nagy
Journal:  PLoS Pathog       Date:  2010-11-04       Impact factor: 6.823

5.  Screening a panel of drugs with diverse mechanisms of action yields potential therapeutic agents against neuroblastoma.

Authors:  Jinesh S Gheeya; Qing-Rong Chen; Christopher D Benjamin; Adam T Cheuk; Patricia Tsang; Joon-Yong Chung; Belhu B Metaferia; Thomas C Badgett; Peter Johansson; Jun S Wei; Stephen M Hewitt; Javed Khan
Journal:  Cancer Biol Ther       Date:  2009-12-27       Impact factor: 4.742

6.  Rck/p54 interacts with APP mRNA as part of a multi-protein complex and enhances APP mRNA and protein expression in neuronal cell lines.

Authors:  Oleg Broytman; Pamela R Westmark; Zafer Gurel; James S Malter
Journal:  Neurobiol Aging       Date:  2008-04-02       Impact factor: 4.673

7.  Elongation Factor 1A-1 Is a Mediator of Hepatocyte Lipotoxicity Partly through Its Canonical Function in Protein Synthesis.

Authors:  Alexandra M Stoianov; Debra L Robson; Alexandra M Hetherington; Cynthia G Sawyez; Nica M Borradaile
Journal:  PLoS One       Date:  2015-06-23       Impact factor: 3.240

8.  Specific Interaction between eEF1A and HIV RT Is Critical for HIV-1 Reverse Transcription and a Potential Anti-HIV Target.

Authors:  Dongsheng Li; Ting Wei; Daniel J Rawle; Fangyun Qin; Rui Wang; Dinesh C Soares; Hongping Jin; Haran Sivakumaran; Min-Hsuan Lin; Kirsten Spann; Catherine M Abbott; David Harrich
Journal:  PLoS Pathog       Date:  2015-12-01       Impact factor: 6.823

Review 9.  Immunosuppressive peptides and their therapeutic applications.

Authors:  Kathrin Thell; Roland Hellinger; Gernot Schabbauer; Christian W Gruber
Journal:  Drug Discov Today       Date:  2013-12-11       Impact factor: 7.851

10.  Structural models of human eEF1A1 and eEF1A2 reveal two distinct surface clusters of sequence variation and potential differences in phosphorylation.

Authors:  Dinesh C Soares; Paul N Barlow; Helen J Newbery; David J Porteous; Catherine M Abbott
Journal:  PLoS One       Date:  2009-07-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.